A Phase 1/2 interventional study of BNT162a1 and BNT162b1 in Infections, Respiratory, Virus Diseases and Infection Viral, sponsored by BioNTech SE. Completed at 5 sites in Germany. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-12.
Sponsored by BioNTech SE · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing BNT162 Vaccine in COVID-19 — 4 open to participants now, 6 under way, 1 of them phase 3. BNT162 Vaccine · COVID-19.
Among the 54 studies testing BNT162 Vaccine in COVID-19, this one is the 31st largest by enrollment, is one of 5 that started in 2020, is one of 3 in phase 1/2, and was the 2nd registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →4 of the 54 studies testing BNT162 Vaccine in COVID-19 are open now, in 6 countries. Recruiting first, the newest first:
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
BioNTech SE · Sites in United States
Ages 18–64 · Healthy volunteers
Technical University of Munich · Sites in Austria, Belgium, Germany and 2 more countries
Ages 3 mo–4 mo · Healthy volunteers
PharmaJet, Inc. · Sites in United States
Ages 18–50 · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 24 · Phase 3 23 · Phase 4 11
First in 2020; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 512 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 575 across the 54 interventional studies. Of the 39 that completed or were terminated, 28 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 54 have an industry lead sponsor. The 10 most frequent:
BioNTech SE is the lead sponsor of 76 studies on the registry; 25 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.
35 studies in COVID-19 by BioNTech SE: 2 open now, 2 under way, 1 of them phase 3. Of 31 finished, 25 (81%) have results posted.
Among the 35 studies in COVID-19 by BioNTech SE, this one is the 23rd largest by enrollment, is one of 10 that started in 2020, is one of 4 in phase 1/2, and was the 2nd registered.
BioNTech SE’s COVID-19 studies by the year they started, since 2020.
3 of the studies testing BNT162 Vaccine in COVID-19 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07730450BioNTech SEA Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age | 2027-08-20 |
| NCT06452654Technical University of MunichAnti-viral Action Against Type 1 Diabetes Autoimmunity | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 54 studies testing BNT162 Vaccine in COVID-19, from their registry updates:
Among BioNTech SE’s 35 in COVID-19:
This tab as a report to print or save as PDF → With an account.
Originally, the study was planned to include two parts, i.e., Part A and Part B, however Part B was cancelled due to changes in the overall clinical development plan. The objectives originally described for Part B have been implemented in the ongoing development via a pivotal Phase I/II/III trial BNT162-02/C4591001 (ClinicalTrials.gov NCT: 04368728).
The conducted Part A was a dose-finding part to investigate the optimal dose of four different vaccines (BNT162a1, BNT162b1, BNT162b2, and BNT162c2), allowing dose adjustments upwards and downwards in younger participants. Doses tested in older participants and expansion cohorts were chosen based on acceptability of dosing in younger participants.
The vaccines BNT162a1, BNT162b1, BNT162b2, and BNT162c2 were administered using a Prime/Boost (P/B) regimen with two doses given \~21 days apart. The vaccine BNT162c2 was also administered using a Single dose (SD) regimen. Four additional expansion cohorts (cohorts 11, 12, 13, and 14) aged from 18 to 85 years received BNT162b2 using a P/B regimen only. In cohort 11, participants received BNT162b2 using one 3 μg prime dose (Dose 1) and one 30 μg boost dose (Dose 2) of BNT162b2. Participants in cohorts 12, 13, and 14 received two doses of BNT162b2 30 µg, each.
This study was a multi-site, Phase I/II, open-label, dose-escalation study. The study included the first-in-human (FIH) dose and dose ranging groups for all four vaccines in healthy younger participants (aged 18 to 55 years [years]) and older participants (aged 56 to 85 years). The conducted Part A followed a dose escalation design. Discretionary dose de-escalation and refinement was also planned. Study participants with the FIH immunization and any subsequent dose escalation cohorts were immunized using a sentinel dosing/subject staggering. For any dose de-escalation or dose-refinement cohorts in younger adults, i.e., cohorts with doses lower than previously tested, participants were dosed using a subject staggering process. Cohorts in older participants were optional and dependent on acceptability of dosing in younger participants. Part A consisted of a treatment phase and a follow-up phase.
For the BNT162a1 3 µg arm, the Safety Review Committee (SRC) decided to stop dosing after 6 treated participants and to not administer the boost immunization (Dose 2). For the BNT162b1 60 µg arm, the SRC decided to not administer the boost immunization (Dose 2) for the 12 participants.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
This study's enrollment of 512 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Browse COVID-19 studies →BioNTech SE is the lead sponsor of 76 studies on the registry; 25 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.
Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Respiratory Tract Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Escalating dose levels
Biological: BNT162a1
Escalating dose levels
Biological: BNT162b1
Escalating dose levels
Biological: BNT162b2
Escalating dose levels
Biological: BNT162c2
Single dose
Biological: BNT162c2
Escalating dose levels
Biological: BNT162b1
Escalating dose levels
Biological: BNT162b2
Fixed doses used; cohort 11: alternative posology dose group expansion cohort; cohort 12: adaptive immune response dose group expansion cohort; cohort 13: immunocompromised (IC) participants expansion cohort
Biological: BNT162b2
fixed doses used; B-cell immune response dose group expansion cohort
Biological: BNT162b2
Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
Number of Participants With Solicited Local Reactions at the Injection Site (Pain, Tenderness, Erythema/Redness, Induration/Swelling) Recorded up to 7 Days After Each IMP Dose.
Solicited local reactions at the injection site (pain, tenderness, erythema/redness, and induration/swelling) were monitored and graded using criteria based on the guidance given in US FDA Guidance for Industry "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials". The reporting of local reactions was based on the participant's assessments via daily solicited reports in the participant diaries.
Time frame: From Day 1 to Day 8 for Dose 1 (Prime Immunization) and from Day 22 to Day 29 for Dose 2 (Boost Immunization)
Number of Participants With Solicited Systemic Reactions (Nausea, Vomiting, Diarrhea, Headache, Fatigue, Myalgia, Arthralgia, Chills, Loss of Appetite, Malaise, and Fever) Recorded up to 7 Days After Each IMP Dose.
Solicited systemic reactions (nausea, vomiting, diarrhea, headache, fatigue, myalgia, arthralgia, chills, loss of appetite, malaise, and fever) were monitored and graded using criteria based on the guidance given in US FDA Guidance for Industry "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials". The reporting of systemic reactions was based on the participant's assessments via daily solicited reports in the participant diaries.
Time frame: From Day 1 to Day 8 for Dose 1 (Prime Immunization) and from Day 22 to Day 29 for Dose 2 (Boost Immunization)
The Percentage of Participants With at Least 1 Unsolicited Treatment Emergent Adverse Event (TEAE) Occurring After Dose 1 (Prime Immunization) up to Dose 2 (Boost Immunization) or 28 Days After Dose 1.
TEAEs without AEs based on solicited reporting via diaries, were analyzed by vaccine, age group, dose level, and for each IMP dose. The percentage of participants reporting at least one TEAE was summarized by adverse event types (any TEAE and any grade \>=3 TEAE) using the Safety Set.
Time frame: 28 days following Dose 1 or up to Dose 2 (whichever was first)
The Percentage of Participants With at Least 1 Unsolicited TEAE Occurring After Dose 1 up to 28 Days After Dose 2 (Boost Immunization) or After Dose 1 (Prime Immunization) (if no Dose 2)
TEAEs, without AEs based on solicited reporting via diaries, were analyzed by vaccine, age group, dose level, and for each IMP dose. The percentage of participants reporting at least one TEAE was summarized by adverse event types (any TEAE and any grade \>=3 TEAE) using the Safety Set.
Time frame: 28 days following Dose 2 or Dose 1 (if no Dose 2 was given)
Functional Antibody Responses (Titers) for BNT162a1, BNT162b1, BNT162b2 (Younger and Older Dose Ranging Cohorts), and BNT162c2 (P/B)
At Day 1 (Baseline = Pre-Prime Immunization) and at 7 and 21 days after Dose 1 (Prime Immunization) and at 7, 21, 28, 63, and 162 days after Dose 2 (Boost Immunization).
Time frame: up to 183 days following Dose 1
Fold Increase in Functional Antibody Titers as Compared to Baseline for BNT162a1, BNT162b1, BNT162b2 (Younger and Older Dose Ranging Cohorts), and BNT162c2 (P/B)
At 7 and 21 days after Dose 1 (Prime Immunization) and at 7, 21, 28, 63, and 162 days after Dose 2 (Boost Immunization).
Time frame: up to 183 days following Dose 1
Number of Participants With Seroconversion Defined as a Minimum of 4-fold Increase of Functional Antibody Titers as Compared to Baseline for BNT162a1, BNT162b1, BNT162b2 (Younger and Older Dose Ranging Cohorts), and BNT162c2 (P/B)
At 7 and 21 days after Dose 1 (Prime Immunization) and at 7, 21, 28, 63, and 162 days after Dose 2 (Boost Immunization).
Time frame: up to 183 days following Dose 1
Functional Antibody Responses (Titers) for BNT162c2 (SD)
At Day 1 (Baseline = Pre Immunization) and at 7, 21, 28, 42, 84, and 183 days after Dose 1 (Prime Immunization).
Time frame: up to 183 days following Dose 1
Fold Increase in Functional Antibody Titers as Compared to Baseline for BNT162c2 (SD)
At 7, 21, 28, 42, 84, and 183 days after Dose 1 (Prime Immunization).
Time frame: up to 183 days following Dose 1
Number of Participants With Seroconversion Defined as a Minimum of 4-fold Increase of Functional Antibody Titers as Compared to Baseline for BNT162c2 (SD)
At 7, 21, 28, 42, 84, and 183 days after Dose 1 (Prime Immunization).
Time frame: up to 183 days following Dose 1
Functional Antibody Responses (Titers) for BNT162b2 (Expansion Cohorts 11, 12, 13, and 14; P/B)
At Day 1 (Baseline = Pre-Prime Immunization) and at 7, 14, and 21 days after Dose 1 (Prime Immunization) and at 7, 14, 21, 28, 63, 162, and 343 days after Dose 2 (Boost Immunization).
Time frame: up to 1 year following Dose 1
Fold Increase in Functional Antibody Titers as Compared to Baseline for BNT162b2 (Expansion Cohorts 11, 12, 13, and 14; P/B)
At 7, 14, and 21 days after Dose 1 (Prime Immunization) and at 7, 14, 21, 28, 63, 162, and 343 days after Dose 2 (Boost Immunization).
Time frame: up to 1 year following Dose 1
Number of Participants With Seroconversion Defined as a Minimum of 4-fold Increase of Functional Antibody Titers as Compared to Baseline for BNT162b2 (Expansion Cohorts 11, 12, 13, and 14; P/B)
At 7, 14, and 21 days after Dose 1 (Prime Immunization) and at 7, 14, 21, 28, 63, 162, and 343 days after Dose 2 (Boost Immunization).
Time frame: up to 1 year following Dose 1
Study participants were selected from the volunteer panel at the clinical CRO, volunteers who responded to either generic or study-specific advertisements in social media, or volunteers who contacted the clinical CRO via a web-based study participant recruitment portal. Study participants were selected from this pool of volunteers according to inclusion and exclusion criteria. The first participant was enrolled on 23 APR 2020.
| Milestone | BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μg | BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μg | BNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μg | BNT162b2 - Part A Immunocompromised (IC) Participants Aged 18 to 85 Years - 30 μg HIV (Cohort 13) | BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg Post-transplant (Cohort 13) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg (Cohort 11) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 12) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 14) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg Single Dose (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (SD) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 12 | 12 | 6 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 15 | 15 | 30 | 90 | 20 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 |
| Completed end of treatment | 12 | 12 | 6 | 12 | 12 | 11 | 10 | 11 | 11 | 12 | 12 | 12 | 12 | 11 | 12 | 11 | 12 | 12 | 12 | 12 | 12 | 15 | 15 | 30 | 89 | 19 | 12 | 12 | 12 | 11 | 12 | 12 | 11 | 12 |
| Completed end of follow-up phase | 12 | 12 | 6 | 12 | 12 | 11 | 10 | 11 | 11 | 11 | 12 | 11 | 12 | 11 | 12 | 11 | 11 | 12 | 12 | 11 | 11 | 0 | 0 | 0 | 0 | 19 | 12 | 12 | 12 | 10 | 12 | 12 | 11 | 11 |
| Completed | 12 | 12 | 6 | 12 | 12 | 11 | 10 | 11 | 11 | 11 | 12 | 11 | 12 | 11 | 12 | 11 | 11 | 12 | 12 | 11 | 11 | 0 | 0 | 0 | 0 | 19 | 12 | 12 | 12 | 10 | 12 | 12 | 11 | 11 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 15 | 15 | 30 | 90 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 1 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Withdrew: Private reason(s) | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Roll-over into trial bnt162-14 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 11 | 10 | 31 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Non-trial sars-cov-2 vaccination due to covid-19 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 2 | 16 | 55 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Solicited local reactions at the injection site (pain, tenderness, erythema/redness, and induration/swelling) were monitored and graded using criteria based on the guidance given in US FDA Guidance for Industry "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials". The reporting of local reactions was based on the participant's assessments via daily solicited reports in the participant diaries.
| Participants | BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μg | BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μg | BNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μg | BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg HIV (Cohort 13) | BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg Post-transplant (Cohort 13) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg (Cohort 11) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 12) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 14) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (SD) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prime up to Day 7 after Prime: Number of participants with any local reaction | 9 | 11 | 6 | 6 | 5 | 10 | 12 | 11 | 12 | 12 | 7 | 11 | 11 | 6 | 9 | 12 | 12 | 10 | 7 | 9 | 9 | 12 | 14 | 16 | 82 | 20 | 4 | 3 | 8 | 11 | 4 | 7 | 5 | 11 |
| Prime up to Day 7 after Prime: Number of participants with any severe/grade >= 3 local reaction | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 4 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Boost up to Day 7 after Boost: Number of participants with any local reaction | 3 | 10 | — | 7 | 5 | 10 | 11 | 11 | 11 | — | 8 | 9 | 9 | 4 | 8 | 10 | 10 | 11 | 7 | 8 | 10 | 12 | 11 | 27 | 79 | 19 | 3 | 5 | 7 | 8 | — | — | — | — |
| Boost up to Day 7 after Boost: Number of participants with any severe/grade >= 3 local reaction | 0 | 0 | — | 2 | 0 | 0 | 0 | 2 | 3 | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | — | — | — | — |
Solicited systemic reactions (nausea, vomiting, diarrhea, headache, fatigue, myalgia, arthralgia, chills, loss of appetite, malaise, and fever) were monitored and graded using criteria based on the guidance given in US FDA Guidance for Industry "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials". The reporting of systemic reactions was based on the participant's assessments via daily solicited reports in the participant diaries.
| Participants | BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μg | BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μg | BNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μg | BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg HIV (Cohort 13) | BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg Post-transplant (Cohort 13) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg (Cohort 11) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 12) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 14) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (SD) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prime up to Day 7 after Prime: Number of participants with any systemic reaction | 6 | 12 | 6 | 9 | 8 | 8 | 11 | 11 | 12 | 12 | 9 | 10 | 11 | 9 | 9 | 12 | 9 | 9 | 3 | 4 | 9 | 12 | 14 | 12 | 68 | 15 | 5 | 8 | 9 | 12 | 7 | 7 | 4 | 8 |
| Prime up to Day 7 after Prime: Number of participants with any severe / grade >= 3 systemic reaction | 1 | 1 | 5 | 0 | 0 | 1 | 2 | 3 | 5 | 8 | 1 | 1 | 2 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 5 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 2 |
| Boost up to Day 7 after Boost: Number of participants with any systemic reaction | 3 | 12 | — | 7 | 7 | 9 | 10 | 11 | 11 | — | 8 | 10 | 12 | 4 | 2 | 7 | 10 | 10 | 4 | 8 | 11 | 13 | 12 | 21 | 78 | 16 | 3 | 7 | 6 | 9 | — | — | — | — |
| Boost up to Day 7 after Boost: Number of participants with any severe / grade >= 3 systemic reaction | 0 | 4 | — | 3 | 1 | 5 | 5 | 6 | 5 | — | 2 | 2 | 4 | 0 | 0 | 1 | 1 | 3 | 1 | 0 | 2 | 4 | 1 | 4 | 14 | 3 | 1 | 1 | 0 | 2 | — | — | — | — |
TEAEs without AEs based on solicited reporting via diaries, were analyzed by vaccine, age group, dose level, and for each IMP dose. The percentage of participants reporting at least one TEAE was summarized by adverse event types (any TEAE and any grade \>=3 TEAE) using the Safety Set.
| percentage of participants | BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μg | BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μg | BNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μg | BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg HIV (Cohort 13) | BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg Post-transplant (Cohort 13) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg (Cohort 11) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 12) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 14) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (SD) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any TEAE | 8 | 33 | 83 | 8 | 0 | 50 | 33 | 42 | 42 | 58 | 25 | 17 | 58 | 25 | 50 | 50 | 8 | 42 | 25 | 33 | 25 | 7 | 53 | 13 | 26 | 35 | 17 | 33 | 17 | 17 | 50 | 58 | 25 | 25 |
| Any grade >=3 TEAE | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 0 | 0 | 0 | 8 | 8 | 8 | 0 | 0 | 8 | 0 | 0 | 0 | 0 | 17 | 0 | 7 | 0 | 2 | 5 | 0 | 0 | 0 | 8 | 0 | 0 | 0 | 0 |
TEAEs, without AEs based on solicited reporting via diaries, were analyzed by vaccine, age group, dose level, and for each IMP dose. The percentage of participants reporting at least one TEAE was summarized by adverse event types (any TEAE and any grade \>=3 TEAE) using the Safety Set.
| percentage of participants | BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μg | BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μg | BNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μg | BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg HIV (Cohort 13) | BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg Post-transplant (Cohort 13) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg (Cohort 11) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 12) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 14) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg (P/B) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any TEAE | 17 | 33 | 83 | 58 | 8 | 75 | 50 | 58 | 67 | 58 | 25 | 33 | 75 | 58 | 58 | 67 | 25 | 50 | 33 | 58 | 33 | 13 | 73 | 40 | 49 | 45 | 33 | 42 | 33 | 17 |
| Any grade >=3 TEAE | 0 | 0 | 0 | 0 | 0 | 0 | 25 | 0 | 0 | 0 | 8 | 8 | 17 | 0 | 0 | 8 | 0 | 0 | 8 | 8 | 17 | 0 | 7 | 3 | 4 | 10 | 0 | 8 | 0 | 8 |
At Day 1 (Baseline = Pre-Prime Immunization) and at 7 and 21 days after Dose 1 (Prime Immunization) and at 7, 21, 28, 63, and 162 days after Dose 2 (Boost Immunization).
| titer | BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μg | BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μg | BNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μg | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg (P/B) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 (Baseline = Pre-Prime Immunization) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.1 (4.8 to 5.5) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 6.9 (3.4 to 13.8) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) |
| 7 days after Dose 1 (Day 8) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.1 (4.8 to 5.5) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 8.2 (2.8 to 24.1) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) |
| 21 days after Dose 1 (Day 22) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 10.0 (6.1 to 16.3) | 6.9 (4.4 to 10.7) | 10.0 (5.4 to 18.5) | 11.7 (6.2 to 22.1) | 29.1 (13.5 to 63.0) | 20.6 (11.5 to 37.0) | 13.7 (7.5 to 25.3) | 16.3 (7.7 to 34.5) | 15.4 (7.8 to 30.4) | 16.3 (8.3 to 32.3) | 5.3 (4.7 to 6.0) | 7.5 (5.6 to 10.1) | 16.6 (9.7 to 28.3) | 16.3 (8.0 to 33.5) | 15.9 (9.6 to 26.2) | 8.4 (5.6 to 12.6) | 7.9 (5.2 to 12.1) | 49.0 (18.3 to 131.4) | 5.0 (5.0 to 5.0) | 5.3 (4.7 to 6.0) | 5.3 (4.7 to 6.0) | 7.1 (4.9 to 10.2) |
| 7 days after Dose 2 (Day 29) | — | — | — | — | 55.0 (32.5 to 93.1) | — | 181.5 (107.5 to 306.3) | — | — | — | 320.0 (183.6 to 557.7) | 169.5 (70.3 to 408.7) | 207.5 (94.0 to 458.0) | 38.9 (16.1 to 93.5) | 134.5 (82.2 to 220.1) | 40.0 (NA to NA) | 213.6 (114.7 to 397.7) | 329.4 (203.2 to 533.9) | 127.0 (79.2 to 203.7) | 164.7 (77.0 to 352.0) | 678.1 (395.9 to 1161.2) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.3 (4.7 to 6.0) | 8.0 (4.8 to 13.4) |
| 21 days after Dose 2 (Day 43) | 5.0 (5.0 to 5.0) | 8.7 (3.8 to 19.8) | 5.3 (4.6 to 6.1) | 69.2 (33.0 to 145.4) | 95.1 (47.0 to 192.7) | 62.2 (30.4 to 127.0) | 160.0 (90.3 to 283.6) | 184.9 (96.8 to 353.0) | 282.1 (136.8 to 581.6) | 8.9 (6.1 to 13.0) | 293.4 (179.9 to 478.5) | 95.1 (42.3 to 214.0) | 134.5 (66.8 to 270.8) | 49.9 (26.9 to 92.6) | 109.9 (71.1 to 169.8) | 187.3 (119.9 to 292.6) | 164.7 (89.3 to 303.6) | 300.5 (182.7 to 494.1) | 134.5 (84.5 to 214.1) | 169.5 (115.3 to 249.2) | 452.5 (255.6 to 801.1) | 5.1 (4.8 to 5.5) | 5.6 (4.9 to 6.5) | 5.7 (4.8 to 6.6) | 6.0 (4.6 to 8.0) |
| 28 days after Dose 2 (Day 50) | 5.0 (NA to NA) | — | — | — | 80.0 (36.1 to 177.5) | — | 82.3 (37.4 to 181.1) | — | — | — | 226.3 (120.5 to 424.8) | 89.8 (37.5 to 214.9) | 95.1 (50.9 to 178.0) | 36.4 (20.8 to 63.8) | 67.3 (35.7 to 126.7) | 190.3 (118.4 to 305.7) | 160.0 (84.6 to 302.5) | 213.6 (148.8 to 306.6) | 127.0 (75.7 to 213.0) | 132.4 (91.8 to 191.0) | 391.7 (229.4 to 668.8) | 5.0 (5.0 to 5.0) | 5.9 (5.0 to 7.1) | 5.0 (5.0 to 5.0) | 5.3 (4.7 to 6.0) |
| 63 days after Dose 2 (Day 85) | 5.0 (5.0 to 5.0) | 7.5 (3.9 to 14.5) | 5.0 (5.0 to 5.0) | 25.9 (14.6 to 46.0) | 31.7 (14.5 to 69.4) | 40.0 (21.1 to 76.0) | 134.5 (70.0 to 258.6) | 102.9 (58.1 to 182.2) | 120.5 (56.1 to 258.7) | 7.7 (5.2 to 11.4) | 46.2 (25.4 to 84.0) | 33.6 (16.6 to 68.1) | 69.2 (33.8 to 142.0) | 36.4 (19.3 to 68.6) | 33.6 (19.9 to 57.0) | 145.6 (85.5 to 247.8) | 146.7 (80.9 to 265.9) | 160.0 (97.4 to 263.0) | 21.8 (12.1 to 39.2) | 27.4 (17.5 to 42.9) | 80.0 (39.1 to 163.5) | 5.6 (5.0 to 6.3) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.2 (4.7 to 5.8) |
| 162 days after Dose 2 (Day 184) | 5.0 (5.0 to 5.0) | 6.9 (3.4 to 13.8) | 5.0 (5.0 to 5.0) | 10.0 (6.1 to 16.4) | 15.0 (9.0 to 24.8) | 13.7 (8.8 to 21.4) | 27.4 (14.0 to 53.6) | 29.2 (13.9 to 61.2) | 56.6 (22.3 to 143.6) | 5.2 (4.8 to 5.5) | 16.8 (10.0 to 28.2) | 19.4 (10.7 to 35.1) | 65.4 (31.7 to 134.8) | 8.5 (5.6 to 13.0) | 11.2 (7.8 to 16.2) | 21.3 (12.2 to 37.3) | 54.8 (31.5 to 95.5) | 38.9 (20.6 to 73.2) | 26.7 (14.1 to 50.4) | 15.5 (11.8 to 20.5) | 58.4 (30.6 to 111.3) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.8 (4.2 to 7.9) | 10.4 (3.4 to 31.5) |
At 7 and 21 days after Dose 1 (Prime Immunization) and at 7, 21, 28, 63, and 162 days after Dose 2 (Boost Immunization).
| Fold rise | BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μg | BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μg | BNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μg | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg (P/B) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7 days after Dose 1 (Day 8) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.2 (0.8 to 1.7) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) |
| 21 days after Dose 1 (Day 22) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 2.0 (1.2 to 3.3) | 1.4 (0.9 to 2.1) | 2.0 (1.1 to 3.7) | 2.3 (1.2 to 4.4) | 5.8 (2.7 to 12.6) | 4.0 (2.2 to 7.3) | 2.7 (1.5 to 5.1) | 3.3 (1.5 to 6.9) | 3.1 (1.6 to 6.1) | 3.3 (1.7 to 6.5) | 1.1 (0.9 to 1.2) | 1.5 (1.1 to 2.0) | 3.3 (1.9 to 5.7) | 3.3 (1.6 to 6.7) | 3.2 (1.9 to 5.2) | 1.7 (1.1 to 2.5) | 1.6 (1.0 to 2.4) | 7.1 (4.3 to 11.9) | 1.0 (1.0 to 1.0) | 1.1 (0.9 to 1.2) | 1.1 (0.9 to 1.2) | 1.4 (1.0 to 2.0) |
| 7 days after Dose 2 (Day 29) | — | — | — | — | 11.0 (6.5 to 18.6) | — | 36.3 (21.5 to 61.3) | — | — | — | 64.0 (36.7 to 111.5) | 33.9 (14.1 to 81.7) | 41.5 (18.8 to 91.6) | 7.8 (3.2 to 18.7) | 26.9 (16.4 to 44.0) | 8.0 (NA to NA) | 42.7 (22.9 to 79.5) | 65.9 (40.6 to 106.8) | 25.4 (15.8 to 40.7) | 32.9 (15.4 to 70.4) | 98.7 (62.2 to 156.5) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.1 (0.9 to 1.2) | 1.6 (1.0 to 2.7) |
| 21 days after Dose 2 (Day 43) | 1.0 (1.0 to 1.0) | 1.7 (0.8 to 4.0) | 1.1 (0.9 to 1.2) | 13.8 (6.6 to 29.1) | 19.0 (9.4 to 38.5) | 12.4 (6.1 to 25.4) | 32.0 (18.1 to 56.7) | 37.0 (19.4 to 70.6) | 54.7 (26.5 to 112.8) | 1.8 (1.2 to 2.6) | 58.7 (36.0 to 95.7) | 19.0 (8.5 to 42.8) | 26.9 (13.4 to 54.2) | 10.0 (5.4 to 18.5) | 22.0 (14.2 to 34.0) | 37.5 (24.0 to 58.5) | 32.9 (17.9 to 60.7) | 60.1 (36.5 to 98.8) | 26.9 (16.9 to 42.8) | 33.9 (23.1 to 49.8) | 65.9 (45.5 to 95.3) | 1.0 (1.0 to 1.1) | 1.1 (1.0 to 1.3) | 1.1 (1.0 to 1.3) | 1.2 (0.9 to 1.6) |
| 28 days after Dose 2 (Day 50) | 1.0 (NA to NA) | — | — | — | 16.0 (7.2 to 35.5) | — | 16.5 (7.5 to 36.2) | — | — | — | 45.3 (24.1 to 85.0) | 18.0 (7.5 to 43.0) | 19.0 (10.2 to 35.6) | 7.3 (4.2 to 12.8) | 13.5 (7.1 to 25.3) | 38.1 (23.7 to 61.1) | 32.0 (16.9 to 60.5) | 42.7 (29.8 to 61.3) | 25.4 (15.1 to 42.6) | 26.5 (18.4 to 38.2) | 57.0 (38.6 to 84.3) | 1.0 (1.0 to 1.0) | 1.2 (1.0 to 1.4) | 1.0 (1.0 to 1.0) | 1.1 (0.9 to 1.2) |
| 63 days after Dose 2 (Day 85) | 1.0 (1.0 to 1.0) | 1.5 (0.8 to 2.9) | 1.0 (1.0 to 1.0) | 5.2 (2.9 to 9.2) | 6.3 (2.9 to 13.9) | 8.0 (4.2 to 15.2) | 26.9 (14.0 to 51.7) | 20.6 (11.6 to 36.4) | 23.4 (10.8 to 50.4) | 1.5 (1.0 to 2.3) | 9.2 (5.1 to 16.8) | 6.7 (3.3 to 13.6) | 13.8 (6.8 to 28.4) | 7.3 (3.9 to 13.7) | 6.7 (4.0 to 11.4) | 29.1 (17.1 to 49.6) | 29.3 (16.2 to 53.2) | 32.0 (19.5 to 52.6) | 4.4 (2.4 to 7.8) | 5.5 (3.5 to 8.6) | 11.6 (7.3 to 18.7) | 1.1 (1.0 to 1.3) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (0.9 to 1.2) |
| 162 days after Dose 2 (Day 184) | 1.0 (1.0 to 1.0) | 1.4 (0.7 to 2.8) | 1.0 (1.0 to 1.0) | 2.0 (1.2 to 3.3) | 3.0 (1.8 to 5.0) | 2.7 (1.8 to 4.3) | 5.5 (2.8 to 10.7) | 5.8 (2.8 to 12.2) | 11.0 (4.3 to 28.2) | 1.0 (1.0 to 1.1) | 3.4 (2.0 to 5.6) | 3.9 (2.1 to 7.0) | 13.1 (6.3 to 27.0) | 1.7 (1.1 to 2.6) | 2.2 (1.6 to 3.2) | 4.3 (2.4 to 7.5) | 11.0 (6.3 to 19.1) | 7.8 (4.1 to 14.6) | 5.3 (2.8 to 10.1) | 3.1 (2.4 to 4.1) | 11.7 (6.1 to 22.3) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.2 (0.8 to 1.6) | 2.1 (0.7 to 6.3) |
At 7 and 21 days after Dose 1 (Prime Immunization) and at 7, 21, 28, 63, and 162 days after Dose 2 (Boost Immunization).
| Participants | BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μg | BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μg | BNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μg | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg (P/B) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7 days after Dose 1 (Day 8) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| 21 days after Dose 1 (Day 22) | 0 | 0 | 0 | 2 | 1 | 3 | 3 | 7 | 7 | 6 | 5 | 6 | 3 | 0 | 0 | 7 | 5 | 6 | 2 | 2 | 10 | 0 | 0 | 0 | 1 |
| 7 days after Dose 2 (Day 29) | — | — | — | — | 11 | — | 11 | — | — | — | 12 | 12 | 11 | 7 | 12 | 1 | 12 | 12 | 12 | 12 | 12 | 0 | 0 | 0 | 2 |
| 21 days after Dose 2 (Day 43) | 0 | 2 | 0 | 10 | 11 | 9 | 10 | 12 | 11 | 3 | 12 | 11 | 12 | 9 | 12 | 11 | 12 | 11 | 12 | 12 | 12 | 0 | 0 | 0 | 0 |
| 28 days after Dose 2 (Day 50) | 0 | — | — | — | 11 | — | 11 | — | — | — | 12 | 11 | 12 | 9 | 11 | 12 | 12 | 12 | 12 | 11 | 12 | 0 | 0 | 0 | 0 |
| 63 days after Dose 2 (Day 85) | 0 | 2 | 0 | 9 | 8 | 9 | 10 | 11 | 11 | 1 | 10 | 8 | 10 | 8 | 9 | 11 | 12 | 12 | 8 | 7 | 12 | 0 | 0 | 0 | 0 |
| 162 days after Dose 2 (Day 184) | 0 | 1 | 0 | 3 | 6 | 4 | 7 | 8 | 10 | 0 | 5 | 7 | 10 | 3 | 2 | 6 | 10 | 11 | 7 | 4 | 10 | 0 | 0 | 1 | 2 |
At Day 1 (Baseline = Pre Immunization) and at 7, 21, 28, 42, 84, and 183 days after Dose 1 (Prime Immunization).
| titer | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (SD) |
|---|---|---|---|---|
| Day 1 (Baseline = Pre Immunization) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) |
| 7 days after Dose 1 (Day 8) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) |
| 21 days after Dose 1 (Day 22) | 5.1 (4.8 to 5.5) | 5.1 (4.8 to 5.5) | 5.3 (4.7 to 6.0) | 5.5 (4.8 to 6.3) |
| 28 days after Dose 1 (Day 29) | — | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.2 (4.8 to 5.6) |
| 42 days after Dose 1 (Day 43) | 5.1 (4.8 to 5.5) | 5.1 (4.8 to 5.5) | 5.5 (4.5 to 6.6) | 5.1 (4.8 to 5.5) |
| 84 days after Dose 1 (Day 85) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 6.0 (4.0 to 9.2) | 5.0 (5.0 to 5.0) |
| 183 days after Dose 1 (Day 184) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.5 (4.5 to 6.8) | 6.4 (3.7 to 11.3) |
At 7, 21, 28, 42, 84, and 183 days after Dose 1 (Prime Immunization).
| Fold rise | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (SD) |
|---|---|---|---|---|
| 7 days after Dose 1 (Day 8) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) |
| 21 days after Dose 1 (Day 22) | 1.0 (1.0 to 1.1) | 1.0 (1.0 to 1.1) | 1.1 (0.9 to 1.2) | 1.1 (1.0 to 1.3) |
| 28 days after Dose 1 (Day 29) | — | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.1) |
| 42 days after Dose 1 (Day 43) | 1.0 (1.0 to 1.1) | 1.0 (1.0 to 1.1) | 1.1 (0.9 to 1.3) | 1.0 (1.0 to 1.1) |
| 84 days after Dose 1 (Day 85) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.2 (0.8 to 1.8) | 1.0 (1.0 to 1.0) |
| 183 days after Dose 1 (Day 184) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.1 (0.9 to 1.4) | 1.3 (0.7 to 2.3) |
At 7, 21, 28, 42, 84, and 183 days after Dose 1 (Prime Immunization).
| Participants | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (SD) |
|---|---|---|---|---|
| 7 days after Dose 1 (Day 8) | 0 | 0 | 0 | 0 |
| 21 days after Dose 1 (Day 22) | 0 | 0 | 0 | 0 |
| 28 days after Dose 1 (Day 29) | — | 0 | 0 | 0 |
| 42 days after Dose 1 (Day 43) | 0 | 0 | 0 | 0 |
| 84 days after Dose 1 (Day 85) | 0 | 0 | 1 | 0 |
| 183 days after Dose 1 (Day 184) | 0 | 0 | 0 | 1 |
At Day 1 (Baseline = Pre-Prime Immunization) and at 7, 14, and 21 days after Dose 1 (Prime Immunization) and at 7, 14, 21, 28, 63, 162, and 343 days after Dose 2 (Boost Immunization).
| Titer | BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg HIV (Cohort 13) | BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg Post-transplant (Cohort 13) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg (Cohort 11) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 12) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 14) |
|---|---|---|---|---|---|
| Day 1 (Baseline = Pre-Prime Immunization) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.1 (4.9 to 5.3) | 5.0 (5.0 to 5.0) |
| 7 days after Dose 1 (Day 8) | 5.0 (5.0 to 5.0) | 5.0 (5.0 to 5.0) | 5.4 (4.8 to 6.0) | 5.3 (4.7 to 6.1) | 6.6 (4.2 to 10.4) |
| 14 days after Dose 1 (Day 15) | — | — | — | — | 9.5 (4.8 to 18.7) |
| 21 days after Dose 1 (Day 22) | 17.4 (9.8 to 30.9) | 5.2 (4.7 to 5.8) | 5.7 (4.8 to 6.8) | 21.9 (17.5 to 27.3) | 17.9 (9.5 to 33.7) |
| 7 days after Dose 2 (Day 29) | 167.6 (112.0 to 250.7) | 12.0 (5.5 to 26.4) | 30.7 (21.3 to 44.1) | 348.6 (270.8 to 448.8) | 286.8 (183.1 to 449.4) |
| 14 days after Dose 2 (Day 36) | 206.3 (116.8 to 364.3) | 11.5 (5.3 to 24.8) | 149.3 (104.0 to 214.4) | 379.1 (306.0 to 469.6) | — |
| 21 days after Dose 2 (Day 43) | 167.6 (93.8 to 299.2) | 9.8 (4.8 to 19.7) | 119.9 (81.5 to 176.4) | 307.8 (250.0 to 378.9) | — |
| 28 days after Dose 2 (Day 50) | 136.1 (76.2 to 243.0) | 11.0 (5.1 to 23.7) | 87.7 (62.3 to 123.7) | 266.5 (215.9 to 328.8) | 103.3 (70.8 to 150.6) |
| 63 days after Dose 2 (Day 85) | 50.4 (30.7 to 82.7) | 8.3 (5.0 to 13.7) | 79.1 (56.7 to 110.2) | 99.9 (81.3 to 122.7) | — |
| 162 days after Dose 2 (Day 184) | 27.0 (16.3 to 44.6) | 11.9 (4.0 to 35.3) | 19.2 (11.9 to 30.9) | 29.5 (23.5 to 37.1) | 49.8 (33.3 to 74.4) |
| 343 days after Dose 2 (Day 365) | — | — | 7.1 (NA to NA) | 30.2 (11.7 to 78.2) | — |
At 7, 14, and 21 days after Dose 1 (Prime Immunization) and at 7, 14, 21, 28, 63, 162, and 343 days after Dose 2 (Boost Immunization).
| Fold rise | BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg HIV (Cohort 13) | BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg Post-transplant (Cohort 13) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg (Cohort 11) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 12) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 14) |
|---|---|---|---|---|---|
| 7 days after Dose 1 (Day 8) | 1.0 (1.0 to 1.0) | 1.0 (1.0 to 1.0) | 1.1 (1.0 to 1.2) | 1.0 (1.0 to 1.1) | 1.3 (0.8 to 2.1) |
| 14 days after Dose 1 (Day 15) | — | — | — | — | 1.9 (1.0 to 3.7) |
| 21 days after Dose 1 (Day 22) | 3.5 (2.0 to 6.2) | 1.0 (0.9 to 1.2) | 1.1 (1.0 to 1.4) | 4.3 (3.5 to 5.3) | 3.6 (1.9 to 6.7) |
| 7 days after Dose 2 (Day 29) | 33.5 (22.4 to 50.1) | 2.4 (1.1 to 5.3) | 6.1 (4.3 to 8.8) | 68.4 (53.3 to 87.7) | 57.4 (36.6 to 89.9) |
| 14 days after Dose 2 (Day 36) | 41.3 (23.4 to 72.9) | 2.3 (1.1 to 5.0) | 29.9 (20.8 to 42.9) | 74.3 (60.2 to 91.8) | — |
| 21 days after Dose 2 (Day 43) | 33.5 (18.8 to 59.8) | 2.0 (1.0 to 3.9) | 24.0 (16.3 to 35.3) | 60.4 (49.2 to 74.1) | — |
| 28 days after Dose 2 (Day 50) | 27.2 (15.2 to 48.6) | 2.2 (1.0 to 4.7) | 17.5 (12.5 to 24.7) | 52.3 (42.7 to 64.0) | 20.7 (14.2 to 30.1) |
| 63 days after Dose 2 (Day 85) | 10.1 (6.1 to 16.5) | 1.7 (1.0 to 2.7) | 15.8 (11.3 to 22.0) | 19.6 (16.0 to 23.9) | — |
| 162 days after Dose 2 (Day 184) | 5.4 (3.3 to 8.9) | 2.4 (0.8 to 7.1) | 3.8 (2.4 to 6.2) | 5.8 (4.6 to 7.2) | 10.0 (6.7 to 14.9) |
| 343 days after Dose 2 (Day 365) | — | — | 1.4 (NA to NA) | 5.4 (2.1 to 13.8) | — |
At 7, 14, and 21 days after Dose 1 (Prime Immunization) and at 7, 14, 21, 28, 63, 162, and 343 days after Dose 2 (Boost Immunization).
| Participants | BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg HIV (Cohort 13) | BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg Post-transplant (Cohort 13) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg (Cohort 11) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 12) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 14) |
|---|---|---|---|---|---|
| 7 days after Dose 1 (Day 8) | 0 | 0 | 1 | 1 | 2 |
| 14 days after Dose 1 (Day 15) | — | — | — | — | 4 |
| 21 days after Dose 1 (Day 22) | 7 | 0 | 1 | 54 | 9 |
| 7 days after Dose 2 (Day 29) | 15 | 4 | 22 | 88 | 19 |
| 14 days after Dose 2 (Day 36) | 15 | 4 | 30 | 88 | — |
| 21 days after Dose 2 (Day 43) | 15 | 3 | 29 | 89 | — |
| 28 days after Dose 2 (Day 50) | 15 | 4 | 30 | 89 | 19 |
| 63 days after Dose 2 (Day 85) | 13 | 2 | 28 | 84 | — |
| 162 days after Dose 2 (Day 184) | 12 | 3 | 12 | 61 | 18 |
| 343 days after Dose 2 (Day 365) | — | — | 0 | 10 | — |
Collected over Local reactions/systemic events: within 7 days after each IMP dose; SAEs: from Day 1 (Dose 1 [Prime Immunization]) up to Day 387 (approximately 12 months after Dose 2 [Boost Immunization]); Other AEs in participants with Dose 2: All AEs from Day 1 up to Day 50 and in addition if assessed as IMP-related from Day 50 up to Day 387; Other AEs in participants without Dose 2: All AEs from Day 1 up to Day 29 and in addition if assessed as IMP-related from Day 29 up to Day 387.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μg | 0/12 (0%) | 0/12 (0%) | 9/12 (75%) |
| BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μg | 0/12 (0%) | 0/12 (0%) | 9/12 (75%) |
| BNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| BNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μg | 0/12 (0%) | 0/12 (0%) | 9/12 (75%) |
| BNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μg | 0/12 (0%) | 0/12 (0%) | 2/12 (16.7%) |
| BNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μg | 0/12 (0%) | 0/12 (0%) | 12/12 (100%) |
| BNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μg | 0/12 (0%) | 0/12 (0%) | 6/12 (50%) |
| BNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μg | 0/12 (0%) | 0/12 (0%) | 12/12 (100%) |
| BNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μg | 0/12 (0%) | 0/12 (0%) | 12/12 (100%) |
| BNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μg | 0/12 (0%) | 0/12 (0%) | 12/12 (100%) |
| BNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μg | 0/12 (0%) | 0/12 (0%) | 3/12 (25%) |
| BNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μg | 0/12 (0%) | 2/12 (16.7%) | 4/12 (33.3%) |
| BNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μg | 0/12 (0%) | 0/12 (0%) | 9/12 (75%) |
| BNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μg | 0/12 (0%) | 0/12 (0%) | 8/12 (66.7%) |
| BNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μg | 0/12 (0%) | 0/12 (0%) | 7/12 (58.3%) |
| BNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μg | 0/12 (0%) | 0/12 (0%) | 12/12 (100%) |
| BNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μg | 0/12 (0%) | 0/12 (0%) | 10/12 (83.3%) |
| BNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μg | 0/12 (0%) | 0/12 (0%) | 11/12 (91.7%) |
| BNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μg | 0/12 (0%) | 1/12 (8.3%) | 4/12 (33.3%) |
| BNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μg | 0/12 (0%) | 3/12 (25%) | 7/12 (58.3%) |
| BNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μg | 0/12 (0%) | 0/12 (0%) | 4/12 (33.3%) |
| BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg HIV (Cohort 13) | 0/15 (0%) | 0/15 (0%) | 3/15 (20%) |
| BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg Post-transplant (Cohort 13) | 0/15 (0%) | 3/15 (20%) | 11/15 (73.3%) |
| BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg (Cohort 11) | 0/30 (0%) | 0/30 (0%) | 13/30 (43.3%) |
| BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 12) | 1/90 (1.1%) | 3/90 (3.3%) | 48/90 (53.3%) |
| BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 14) | 0/20 (0%) | 1/20 (5%) | 9/20 (45%) |
| BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (P/B) | 0/12 (0%) | 0/12 (0%) | 4/12 (33.3%) |
| BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (P/B) | 0/12 (0%) | 0/12 (0%) | 5/12 (41.7%) |
| BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (P/B) | 0/12 (0%) | 0/12 (0%) | 4/12 (33.3%) |
| BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg (P/B) | 0/12 (0%) | 0/12 (0%) | 2/12 (16.7%) |
| BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (SD) | 0/12 (0%) | 0/12 (0%) | 10/12 (83.3%) |
| BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (SD) | 0/12 (0%) | 0/12 (0%) | 9/12 (75%) |
| BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg (SD) | 0/12 (0%) | 0/12 (0%) | 5/12 (41.7%) |
| BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (SD) | 0/12 (0%) | 1/12 (8.3%) | 11/12 (91.7%) |
| Event | BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μg | BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μg | BNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μg | BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg HIV (Cohort 13) | BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg Post-transplant (Cohort 13) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg (Cohort 11) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 12) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 14) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (SD) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Urinary tract infectionInfections and infestations | 0/12 | 0/12 | 0/6 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/15 | 3/15 | 0/30 | 0/90 | 0/20 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 |
| SyncopeNervous system disorders | 0/12 | 0/12 | 0/6 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 1/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/15 | 0/15 | 0/30 | 0/90 | 0/20 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 |
| Ankle fractureInjury, poisoning and procedural complications | 0/12 | 0/12 | 0/6 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 1/12 | 0/12 | 0/15 | 0/15 | 0/30 | 0/90 | 0/20 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 |
| Pelvic massGeneral disorders | 0/12 | 0/12 | 0/6 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 1/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/15 | 0/15 | 0/30 | 0/90 | 0/20 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 |
| Diverticulum intestinal haemorrhagicGastrointestinal disorders | 0/12 | 0/12 | 0/6 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 1/12 | 0/12 | 0/12 | 0/15 | 0/15 | 0/30 | 0/90 | 0/20 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 |
| Inguinal herniaGastrointestinal disorders | 0/12 | 0/12 | 0/6 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 1/12 | 0/12 | 0/15 | 0/15 | 0/30 | 0/90 | 0/20 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 |
| Oesophageal carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/12 | 0/12 | 0/6 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 1/12 | 0/12 | 0/15 | 0/15 | 0/30 | 0/90 | 0/20 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 |
| COVID-19Infections and infestations | 0/12 | 0/12 | 0/6 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/15 | 0/15 | 0/30 | 0/90 | 0/20 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 1/12 |
| Umbilical herniaGastrointestinal disorders | 0/12 | 0/12 | 0/6 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/15 | 0/15 | 0/30 | 0/90 | 1/20 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 |
| CystitisInfections and infestations | 0/12 | 0/12 | 0/6 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/15 | 0/15 | 0/30 | 1/90 | 0/20 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 |
| Event | BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μg | BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μg | BNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μg | BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg HIV (Cohort 13) | BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg Post-transplant (Cohort 13) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg (Cohort 11) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 12) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 14) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (SD) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Injection site reactionGeneral disorders | 9/12 | 8/12 | 1/6 | 4/12 | 0/12 | 8/12 | 0/12 | 11/12 | 12/12 | 6/12 | 0/12 | 0/12 | 0/12 | 2/12 | 0/12 | 11/12 | 9/12 | 10/12 | 0/12 | 0/12 | 0/12 | 0/15 | 0/15 | 1/30 | 0/90 | 0/20 | 0/12 | 0/12 | 1/12 | 0/12 | 1/12 | 2/12 | 3/12 | 9/12 |
| Influenza like illnessGeneral disorders | 3/12 | 8/12 | 1/6 | 4/12 | 0/12 | 8/12 | 0/12 | 10/12 | 11/12 | 10/12 | 0/12 | 0/12 | 0/12 | 2/12 | 0/12 | 7/12 | 2/12 | 4/12 | 2/12 | 0/12 | 0/12 | 0/15 | 2/15 | 0/30 | 0/90 | 0/20 | 0/12 | 0/12 | 0/12 | 1/12 | 2/12 | 2/12 | 0/12 | 2/12 |
| HeadacheNervous system disorders | 2/12 | 1/12 | 1/6 | 5/12 | 0/12 | 8/12 | 1/12 | 8/12 | 5/12 | 2/12 | 1/12 | 0/12 | 1/12 | 0/12 | 1/12 | 4/12 | 2/12 | 1/12 | 1/12 | 2/12 | 3/12 | 0/15 | 2/15 | 3/30 | 10/90 | 2/20 | 1/12 | 1/12 | 1/12 | 0/12 | 4/12 | 3/12 | 1/12 | 5/12 |
| FatigueGeneral disorders | 1/12 | 1/12 | 1/6 | 7/12 | 0/12 | 6/12 | 0/12 | 5/12 | 1/12 | 0/12 | 0/12 | 0/12 | 0/12 | 2/12 | 1/12 | 4/12 | 5/12 | 1/12 | 0/12 | 0/12 | 0/12 | 0/15 | 0/15 | 0/30 | 2/90 | 0/20 | 0/12 | 0/12 | 0/12 | 0/12 | 3/12 | 4/12 | 2/12 | 3/12 |
| Injection site discomfortGeneral disorders | 0/12 | 0/12 | 0/6 | 1/12 | 0/12 | 5/12 | 0/12 | 3/12 | 1/12 | 1/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/15 | 0/15 | 0/30 | 0/90 | 0/20 | 0/12 | 0/12 | 0/12 | 0/12 | 2/12 | 3/12 | 0/12 | 0/12 |
| Injection site painGeneral disorders | 0/12 | 0/12 | 0/6 | 3/12 | 0/12 | 4/12 | 0/12 | 3/12 | 1/12 | 3/12 | 0/12 | 2/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 1/12 | 0/12 | 0/12 | 0/15 | 0/15 | 0/30 | 2/90 | 2/20 | 0/12 | 0/12 | 0/12 | 0/12 | 3/12 | 2/12 | 0/12 | 1/12 |
| Periorbital discomfortEye disorders | 0/12 | 0/12 | 2/6 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/15 | 0/15 | 0/30 | 0/90 | 0/20 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 |
| Decreased appetiteMetabolism and nutrition disorders | 0/12 | 0/12 | 0/6 | 2/12 | 0/12 | 0/12 | 0/12 | 1/12 | 3/12 | 0/12 | 0/12 | 1/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/15 | 1/15 | 0/30 | 0/90 | 0/20 | 1/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 1/12 |
| PollakiuriaRenal and urinary disorders | 0/12 | 0/12 | 0/6 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 3/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/15 | 0/15 | 0/30 | 0/90 | 0/20 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 |
| PalpitationsCardiac disorders | 0/12 | 0/12 | 1/6 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 1/12 | 0/12 | 0/12 | 0/12 | 0/15 | 0/15 | 0/30 | 0/90 | 0/20 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 | 0/12 |
| Age, Continuous(years) | BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μg | BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μg | BNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μg | BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg HIV (Cohort 13) | BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg Post-transplant (Cohort 13) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg (Cohort 11) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 12) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 14) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (SD) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 50.80 ± 2.58 | 48.31 ± 9.04 | 38.22 ± 13.87 | 38.21 ± 10.48 | 41.44 ± 11.27 | 43.62 ± 11.03 | 39.42 ± 11.41 | 35.74 ± 8.60 | 33.88 ± 10.72 | 35.81 ± 12.50 | 64.31 ± 5.89 | 65.66 ± 5.95 | 67.16 ± 6.47 | 36.65 ± 10.14 | 39.64 ± 10.14 | 35.07 ± 10.46 | 42.75 ± 9.89 | 47.21 ± 6.43 | 65.44 ± 7.42 | 65.88 ± 6.56 | 63.87 ± 5.42 | 48.04 ± 10.36 | 48.93 ± 11.87 | 51.92 ± 13.57 | 55.59 ± 16.07 | 48.45 ± 13.87 | 36.42 ± 10.33 | 39.41 ± 12.34 | 34.47 ± 10.24 | 35.42 ± 9.68 | 40.03 ± 14.67 | 35.23 ± 11.88 | 42.40 ± 12.04 | 32.60 ± 10.87 | 47.00 ± 15.34 |
| Sex: Female, Male(Participants) | BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μg | BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μg | BNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μg | BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg HIV (Cohort 13) | BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg Post-transplant (Cohort 13) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg (Cohort 11) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 12) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 14) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (SD) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 5 | 6 | 1 | 7 | 6 | 8 | 4 | 4 | 6 | 5 | 5 | 10 | 8 | 5 | 7 | 8 | 10 | 4 | 4 | 6 | 8 | 3 | 9 | 13 | 45 | 10 | 8 | 5 | 3 | 8 | 10 | 8 | 5 | 7 | 261 |
| Male | 7 | 6 | 5 | 5 | 6 | 4 | 8 | 8 | 6 | 7 | 7 | 2 | 4 | 7 | 5 | 4 | 2 | 8 | 8 | 6 | 4 | 12 | 6 | 17 | 45 | 10 | 4 | 7 | 9 | 4 | 2 | 4 | 7 | 5 | 251 |
| Ethnicity (NIH/OMB)(Participants) | BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μg | BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μg | BNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μg | BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg HIV (Cohort 13) | BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg Post-transplant (Cohort 13) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg (Cohort 11) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 12) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 14) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (SD) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 6 |
| Not Hispanic or Latino | 12 | 12 | 6 | 11 | 12 | 12 | 12 | 12 | 12 | 11 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 15 | 15 | 30 | 89 | 20 | 12 | 12 | 10 | 12 | 12 | 11 | 12 | 12 | 506 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μg | BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μg | BNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μg | BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg HIV (Cohort 13) | BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg Post-transplant (Cohort 13) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg (Cohort 11) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 12) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 14) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (SD) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| White | 12 | 12 | 5 | 12 | 12 | 11 | 11 | 12 | 12 | 11 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 14 | 15 | 30 | 89 | 19 | 11 | 11 | 12 | 12 | 12 | 11 | 12 | 12 | 502 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Region of Enrollment(participants) | BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μg | BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μg | BNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μg | BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg HIV (Cohort 13) | BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg Post-transplant (Cohort 13) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg (Cohort 11) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 12) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 14) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (SD) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Germany | 12 | 12 | 6 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 15 | 15 | 30 | 90 | 20 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 512 |
| Weight(kg) | BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μg | BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μg | BNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μg | BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg HIV (Cohort 13) | BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg Post-transplant (Cohort 13) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg (Cohort 11) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 12) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 14) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (SD) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 77.68 ± 7.59 | 72.54 ± 10.85 | 78.58 ± 14.93 | 72.99 ± 14.79 | 77.11 ± 14.07 | 71.57 ± 14.09 | 73.58 ± 11.88 | 79.84 ± 13.81 | 76.73 ± 13.32 | 78.70 ± 13.85 | 71.90 ± 10.98 | 70.38 ± 9.14 | 69.98 ± 8.06 | 80.18 ± 14.13 | 77.08 ± 10.84 | 76.11 ± 11.67 | 72.45 ± 10.97 | 77.78 ± 8.43 | 77.87 ± 9.78 | 76.91 ± 12.38 | 75.80 ± 11.98 | 73.85 ± 9.67 | 73.50 ± 10.07 | 77.79 ± 12.92 | 75.44 ± 13.02 | 79.09 ± 14.94 | 67.45 ± 13.53 | 76.41 ± 15.66 | 72.44 ± 6.86 | 70.94 ± 11.43 | 63.75 ± 6.14 | 73.26 ± 15.39 | 73.48 ± 9.51 | 68.90 ± 11.56 | 74.75 ± 12.27 |
| Body mass index(kg/m^2) | BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.1 μg | BNT162a1 - Part A Participants Aged 18 to 55 Years - 0.3 μg | BNT162a1 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 1 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 10 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 20 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 30 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 50 μg | BNT162b1 - Part A Participants Aged 18 to 55 Years - 60 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 10 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 20 μg | BNT162b1 - Part A Participants Aged 56 to 85 Years - 30 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 1 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 3 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 10 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 20 μg | BNT162b2 - Part A Participants Aged 18 to 55 Years - 30 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 10 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 20 μg | BNT162b2 - Part A Participants Aged 56 to 85 Years - 30 μg | BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg HIV (Cohort 13) | BNT162b2 - Part A IC Participants Aged 18 to 85 Years - 30 μg Post-transplant (Cohort 13) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 3 & 30 μg (Cohort 11) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 12) | BNT162b2 - Part A Participants Aged 18 to 85 Years - 30 μg (Cohort 14) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 3 μg (P/B) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.1 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.3 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 0.6 μg (SD) | BNT162c2 - Part A Participants Aged 18 to 55 Years - 1 μg (SD) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 24.61 ± 3.14 | 24.23 ± 2.78 | 24.73 ± 2.63 | 25.17 ± 2.89 | 24.94 ± 2.68 | 24.20 ± 2.32 | 24.34 ± 2.33 | 25.68 ± 3.44 | 25.52 ± 3.50 | 25.19 ± 3.09 | 24.73 ± 2.46 | 25.59 ± 2.22 | 25.63 ± 2.22 | 25.25 ± 3.26 | 25.50 ± 2.79 | 25.13 ± 2.07 | 25.43 ± 2.34 | 25.01 ± 1.38 | 25.43 ± 2.15 | 25.62 ± 2.47 | 25.85 ± 2.75 | 23.62 ± 1.90 | 25.63 ± 2.82 | 25.53 ± 2.72 | 25.08 ± 2.73 | 26.12 ± 2.96 | 23.31 ± 2.38 | 25.02 ± 2.85 | 23.83 ± 2.39 | 25.06 ± 3.73 | 22.82 ± 1.54 | 24.97 ± 3.17 | 24.19 ± 2.04 | 24.04 ± 2.59 | 24.98 ± 2.69 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2020 to primary completion in Jun 2021, 14 months.
Results were first posted in Jul 2024, 3 years after primary completion.
Of 80 industry-sponsored phase 1/2 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 14 months is above that.
Counting every sponsor, half of 187 studies reached it within 11 months; a quarter within 4 and three quarters within 20.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BNT162 Vaccine